| Antifungal Agent | Dosage Range in Adult Patients* (mg/kg/day) | Dosage in Pediatric Patients* (mg/kg/day) | Toxicity | Comments |
|---|---|---|---|---|
| Amphotericin B deoxycholate | .75-1.0 | .75-1.0 | -Severe nephrotoxicity Infusion-related toxicity Anemia | Higher dosages are more toxic and not necessarily more effective |
| Liposomal amphotericin B (AmBisome®) | 5-10 | 5-10 | -Reduced nephrotoxicity Infusion-related toxicity -Uncommon but severe acute infusion-related toxicity | Higher dosages are more toxic and not necessarily more effective |
| Amphotericin B Lipid Complex (Abele®) | 5.0 | 5.0 | -Reduced nephrotoxicity -Infusion-related toxicity | Higher dosages are more toxic and not necessarily more effective |
| Amphotericin B Colloidal Dispersion (ABCD®) | 5.0 | 5.0 | -Reduced nephrotoxicity -Infusion-related toxicity -Infusion-related respiratory distress | Higher dosages are more toxic and not necessarily more effective |
*Optimal dosage and duration of antifungal therapy for mucormycosis is not well defined. Dosage and duration of therapy outside of a clinical trial are best assessed individually for each patient.